Multiple Follicles on Letrozole: Risk, Reward, and Twins

Your scan showed two, maybe three, follicles approaching trigger size, and now you are sitting with a particular kind of fertility-clinic vertigo, equal parts hope (more chances) and worry (what if it is twins, what if my RE cancels the cycle). The honest numbers on letrozole and twins are that the per-cycle twin rate is around 3 to 4 percent, which is meaningfully lower than clomid, and that the conversation about how many mature follicles is too many depends on more than a single threshold.

This post walks through what the data actually says about multiples on letrozole, why your ovary recruited more than one follicle in the first place, what the obstetric risks of a twin pregnancy look like in real terms, and how clinics decide whether to proceed, cancel, or convert to IVF.

The twin rate on letrozole, by the numbers

The single most cited trial here is PALO, published in the New England Journal of Medicine in 2014. In 750 women with PCOS, randomised to letrozole or clomiphene for up to five treatment cycles, the multiple-pregnancy rate was 3.4 percent on letrozole versus 7.4 percent on clomiphene.¹ Almost all of those were twins; triplets were rare (under half a percent on either drug).

So the headline answer to does letrozole increase chance of twins is yes, compared with no medication at all (the natural twin rate sits at roughly 1 to 2 percent), but less than clomid does. Letrozole's twin rate is roughly half clomid's at standard ovulation induction doses.

Several mechanisms sit behind that difference.

• Letrozole's effect on the brain (oestrogen drop, FSH pulse) is shorter in duration than clomid's (clomid blocks oestrogen receptors for longer because of its long half-life).
• The resulting FSH pulse is enough to recruit a dominant follicle but, in most ovaries, does not over-recruit the way clomid sometimes does.
• The endometrial environment after letrozole is closer to physiological than after clomid, which may slightly favour singleton implantation over double.

In the AMIGOS trial of unexplained infertility, where letrozole was compared with gonadotropins and clomid in non-PCOS couples, the multiple-pregnancy rate on letrozole was again low: about 9 percent of live births in the letrozole arm were multiples, versus 32 percent in the gonadotropin arm.² Different population, but the same pattern: oral letrozole, even with stimulation, produces fewer multiples than injectable gonadotropins.

Why your ovary recruited more than one follicle on letrozole

Not every letrozole cycle produces multiple follicles. The factors that push toward multiple recruitment are reasonably predictable.

• Higher dose: a 7.5mg letrozole cycle is more likely to recruit two or three follicles than a 2.5mg cycle. Some clinics see a small uptick at 5mg over 2.5mg.
• A polycystic ovary: the defining feature of PCOS is a high antral follicle count, often 20 or more small follicles per ovary, waiting in line for an FSH pulse. When the brain gets the letrozole-driven FSH bump, it sometimes recruits more than one of those waiting follicles.
• Super-responder physiology: a small subset of patients recruit two or three follicles even at 2.5mg. This is usually identified after the first cycle.
• Cycle-to-cycle variation: the same person on the same dose can have a one-follicle cycle in March and a three-follicle cycle in May. Ovarian response is not perfectly reproducible.

For someone reading this trying to make sense of a letrozole dose for twins question, the honest answer is that there is no dose that reliably produces twins without also raising the cancellation risk and the obstetric risk of higher-order multiples. Ovulation induction protocols are designed to recruit one mature follicle for a reason, and the twins that happen are a side effect, not a target.

What multiple follicles mean for this specific cycle

Two mature follicles on the scan: the per-cycle pregnancy rate is modestly higher than with one mature follicle, perhaps by a few percentage points, depending on age and other factors. The twin pregnancy rate also rises, from roughly 3 to 4 percent of pregnancies to closer to 10 to 15 percent in cycles where two mature follicles were released.

Three mature follicles: pregnancy rate per cycle does not climb proportionally. The marginal return on additional follicles drops. The risk of multiples, particularly higher-order multiples (triplets), rises in a way most REs are not willing to accept in an ovulation induction cycle.

Four or more mature follicles: most clinics will cancel the cycle. The ASRM committee opinion on multiple gestation associated with infertility therapy specifically addresses this. Triplet and higher-order pregnancies in oral-medication cycles are largely preventable by appropriate cancellation, and most professional societies recommend it.³

The frame I use in clinic is that we are trying to maximise singleton live birth, not gross pregnancy rate. A cancelled cycle is disappointing in the moment but is often the right decision.

The actual obstetric risks of a twin pregnancy

If your scan today shows two mature follicles and you are likely to proceed, you may end up with a singleton, a twin pregnancy, or no pregnancy this cycle. The twin scenario is the one that deserves a calm, specific conversation rather than either panic or dismissal.

Most twins from ovulation induction are dizygotic (fraternal), meaning two eggs were fertilised by two sperm. Each twin develops in its own placenta and amniotic sac, which is the safer of the twin scenarios. Identical (monozygotic) twins do not become more common with letrozole.

Real obstetric risks of a twin pregnancy, drawing on the ACOG multifetal gestation practice bulletin:⁶

• Preterm birth: average gestational age at delivery for twin pregnancy is around 35 to 36 weeks, compared with 39 to 40 weeks for singletons. About 60 percent of twins deliver before 37 weeks.
• Preeclampsia: two to three times the singleton rate.
• Gestational diabetes: slightly higher rate, exacerbated in PCOS-associated pregnancies.
• Caesarean delivery: more than half of twin pregnancies in the United States end in caesarean.
• NICU admission: more common, primarily driven by the higher rate of late preterm and early term deliveries.
• Perinatal mortality: higher than singleton but, with modern obstetric care, still very low in absolute terms in higher-income settings.

These risks are real and worth knowing. They are not catastrophic for most twin pregnancies in modern obstetric care. The conversation worth having is whether your individual situation, age, parity, comorbidities, geography of your obstetric care, and family preferences, makes proceeding with a two-mature-follicle cycle a thoughtful yes or a thoughtful no.

Cancel thresholds: how clinics actually decide

There is no universal cancel rule. Different clinics weight different findings. A reasonable framework I see in practice:

• One mature follicle (18 to 22mm), one or two smaller follicles (10 to 14mm): proceed.
• Two mature follicles, others smaller: proceed in most cases. Twin conversation.
• Three mature follicles greater than 14mm: pause. Discuss cancellation, dose reduction for next cycle, or in select cases conversion to IVF.
• Four or more mature follicles: most clinics cancel timed intercourse and IUI cycles.

PCOS patients with very high antral counts sometimes have a lower cancel threshold because their ovary's tendency to over-recruit is documented. Patient age also factors in. A 40-year-old with three follicles may have a different conversation than a 28-year-old with the same scan, because the older patient's lower per-egg fertility rate partially offsets the multiple-pregnancy risk per follicle.

The chances of twins with letrozole and trigger shot specifically (a common search) come from the per-cycle multiple rate in monitored ovulation induction cycles. If your cycle is monitored with appropriate scan-based cancellation, the twin rate sits in the 3 to 5 percent range for letrozole-trigger-timed-intercourse cycles in PCOS.¹ If your cycle is monitored loosely or not at all, the twin rate is harder to predict, which is one of the arguments for the scan.

What "cycle cancellation" actually looks like

If your cycle is cancelled for too many follicles, here is what typically happens.

You skip the trigger shot. No hCG, no Lupron, nothing. You wait for the cycle to end on its own. The follicles will not all rupture; some will luteinise without releasing an egg, some will eventually regress. Your next period may arrive on a delayed schedule because the corpus luteum activity is unusual.

You are advised not to attempt timed intercourse or IUI during that cycle, both to avoid the multiple-pregnancy risk and because timing without trigger is unreliable in a stimulated cycle.

The next cycle, your RE will typically:

• Reduce the letrozole dose (often 7.5 to 5, or 5 to 2.5).
• Consider an alternate-day dosing strategy.
• Sometimes add metformin if insulin resistance is part of the picture.
• Re-scan more carefully in the new cycle.

A cancelled cycle is not a wasted cycle. It is data. The next cycle is more likely to land in a single-follicle pattern because the dose has been recalibrated.

Conversion to IVF: when and why

In a small number of cases, a clinic will offer to convert an oral-medication cycle to IVF retrieval. The follicles that are already mature get retrieved, fertilised in the lab, and one embryo is transferred (with the rest cryopreserved). This both salvages the cycle and controls the multiple-pregnancy risk by transferring a single embryo.

Conversion to IVF requires:

• A clinic with same-day or next-day procedural availability.
• Willingness on the patient's part to absorb the cost and logistical change.
• A reasonable mature-follicle count (usually three to five).

It is not the right move for everyone, but it is worth knowing about as an option when the scan shows more follicles than a standard ovulation induction cycle can safely use.

What I tell patients with two mature follicles

Two follicles is the most common version of this conversation. The practical version of the talk:

• Twin chance is meaningfully higher than a single-follicle cycle, but the absolute rate is still low (10 to 15 percent of pregnancies, not 50 percent).
• Twin pregnancy in modern obstetrics is mostly fine, with attention to preterm birth risk and gestational complications.
• The choice to proceed is reasonable for most patients in this scenario.
• Discuss this with your partner and your obstetrician before the cycle, not after a positive test, because the obstetric implications are easier to think about in the calm.

What I tell patients with three mature follicles, on letrozole and twins risk

Three is a different conversation.

• The marginal pregnancy benefit is small.
• The marginal multiple-pregnancy risk is real, including a small but non-zero triplet risk.
• Cancellation and a lower dose next cycle is often the right call.
• Conversion to IVF can be discussed if the clinical setting supports it.

Some patients push for proceeding despite the count, often because of time pressure or financial pressure of paying out of pocket for cycles. That is a real conversation, and a doctor's job is to lay out the numbers honestly and respect the decision after that.

What's next

• If you are proceeding with two follicles and want the trigger walkthrough: hCG trigger shot overview
• If you are wondering whether the dose needs to come down next cycle: letrozole dose 2.5, 5, 7.5
• If you are moving up to IUI to better control timing: IUI explained
• If this cycle was cancelled and you need support before the next one: failed letrozole cycle

Related in this cluster

• Follicle Tracking Ultrasounds: What You'll See and Hear

Sources

1. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine 2014;371(2):119-129. https://www.nejm.org/doi/full/10.1056/NEJMoa1313517
2. Diamond MP, Legro RS, Coutifaris C, et al. Letrozole, gonadotropin, or clomiphene for unexplained infertility (AMIGOS trial). New England Journal of Medicine 2015;373(13):1230-1240. https://www.nejm.org/doi/full/10.1056/NEJMoa1414827
3. Practice Committee of the American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertility and Sterility 2012;97(4):825-834. https://doi.org/10.1016/j.fertnstert.2011.11.048
4. Mitwally MFM, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertility and Sterility 2005;83(1):229-231. https://doi.org/10.1016/j.fertnstert.2004.07.952
5. Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertility and Sterility 2006;85(6):1761-1765. https://doi.org/10.1016/j.fertnstert.2006.03.014
6. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 234: Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies. Obstetrics & Gynecology 2021;137(6):e145-e162. https://doi.org/10.1097/AOG.0000000000004397